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Background: The molecular structure of circulating enteric fever pathogens was studied using hospital-based
genomic surveillance in a tertiary care referral centre in South India as a first genomic surveillance study, to our
knowledge, of blood culture-confirmed enteric fever in the region.
Methods: Blood culture surveillance was conducted at St John’s Medical College Hospital, Bengaluru, between
July 2016 and June 2017. The bacterial isolates collected were linked to demographic variables of patients and
subjected to WGS. The resulting pathogen genomic data were also globally contextualized to gauge possible
phylogeographical patterns.
Results: Hospital-based genomic surveillance for enteric fever in Bengaluru, India, identified 101 Salmonella
enterica Typhi and 14 S. Paratyphi A in a 1 year period. Ninety-six percent of isolates displayed non-susceptibility
to fluoroquinolones. WGS showed the dominant pathogen was S. Typhi genotype 4.3.1.2 (H58 lineage II). A
fluoroquinolone-resistant triple-mutant clone of S. Typhi 4.3.1.2 previously associated with gatifloxacin treat-
ment failure in Nepal was implicated in 18% of enteric fever cases, indicating ongoing inter-regional circulation.
Conclusions: Enteric fever in South India continues to be a major public health issue and is strongly associated
with antimicrobial resistance. Robust microbiological surveillance is necessary to direct appropriate treatment
and preventive strategies. Of particular concern is the emergence and expansion of the highly fluoroquinolone-
resistant triple-mutant S. Typhi clone and its ongoing inter- and intra-country transmission in South Asia, which
highlights the need for regional coordination of intervention strategies, including vaccination and longer-term
strategies such as improvements to support hygiene and sanitation.
Introduction
The Indian subcontinent is a high-incidence endemic setting for
enteric fever, a febrile illness caused by Salmonella enterica sero-
vars Typhi (S. Typhi) and Paratyphi A (S. Paratyphi A), which on
a global scale caused an estimated 14.3 million cases of febrile
illness in 2017.1 The inter-regional circulation of antimicrobial-re-
sistant (AMR) S. Typhi within the Indian subcontinent affects the
impoverished and children disproportionally while limiting treat-
ment options. A clade of fluoroquinolone-resistant S. Typhi 4.3.1.2
(H58 lineage II) isolates was previously detected in patients in
Patan, Nepal, between 2011 and 2014. WGS of these S. Typhi
isolates revealed SNPs in three distinct locations of the QRDR2,3 of
genes gyrA (gyrA-S83F and gyrA-D87V) and parC (parC-S80I).
These ‘triple mutants’ displayed MIC 24 mg/L and were respon-
sible for gatifloxacin treatment failure.4 Global contextualization
of these isolates revealed that the triple mutants appeared to
have emerged in India before entering Nepal, circa 2008, where
they underwent a local expansion, infecting both adults and
children.4–6 It is not known whether these fluoroquinolone-
resistant triple mutants remain prevalent in the Indian subcontin-
ent; previous isolates from India were obtained from travellers
returning to the UK from India or from sporadic patients treated at
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tertiary care7 settings without a clear understanding of the
structure of the circulating pathogen population.
Methods
In this study, hospital-based surveillance of inpatients and outpatients was
conducted at St John’s Medical College Hospital, a tertiary care setting in
Bengaluru, South India, which provides care for approximately 3500
patients on an outpatient basis and has a capacity of 2000 inpatient beds.
It is situated in the eastern part of Bengaluru, a city that is densely popu-
lated, holding a population of over 12 million residents. This hospital in
Bengaluru is situated at the confluence of three South Indian states and
receives referrals from neighbouring regions in the states of Tamil Nadu
and Andhra Pradesh in addition to the referrals from the home state of
Karnataka. No surveillance for enteric fever exists in the local public health
system, and tertiary care blood culture-positive data are the only useful
surrogate for enteric fever burden.
Every microbiological specimen that was positive for a typhoidal
Salmonella organism (confirmed by biochemical and serological means)
was included in the study, and tested for antimicrobial susceptibility using
the Kirby–Bauer disc diffusion method and VITEKV
R
, which were reported
using the CLSI interpretive criteria [inhibition zone diameters 31 mm
and MICs 0.06 mg/L for ciprofloxacin and 0.12 mg/L for ofloxacin on
VITEKV
R
2 (bioMe´rieux, France) were considered susceptible].8 These
isolates were subsequently sequenced on the Illumina HiSeq 2500
platform. Raw sequence data have been deposited in the European
Nucleotide Archive under project PRJEB14050, and individual accession
numbers are listed in Tables S1 and S2 (available as Supplementary
data at JAC Online). The data were subjected to SNP and phylogenetic
analyses as described previously.6
Ethics
Ethics approval was obtained from the Oxford Tropical Research Ethics
Committee (OxTREC 586–16) and local institutional approval from the
Institutional Ethics Committee (IEC) at St John’s Research Institute (140/
216) and Health Ministry’s Screening Committee, India.
Results
Over the duration of surveillance, 19641 cultures were performed,
of which 3454 were significant for non-commensal pathogenic
bacteria and 3.3% of these significant blood cultures were positive
for a typhoidal Salmonella organism. Of these, 101 were S. Typhi
and 14 were S. Paratyphi A; 37 (32.2%) were isolated from children
(2 months to 15 years of age) and 78 (67.8%) from adults. All were
susceptible to ampicillin, co-trimoxazole, chloramphenicol, cefo-
taxime, ceftriaxone and azithromycin and no known AMR genes or
plasmids were identified. However, 110 (96%) isolates displayed
non-susceptibility to ciprofloxacin and ofloxacin (Table 1), and all
except one isolate (S. Typhi genotype 2.2.2) were resistant to nali-
dixic acid. These phenotypes were mediated by a variety of QRDR
mutations (Table 1), which were detected in 98% of isolates.
Notably, 21 S. Typhi strains were QRDR triple mutants (Table 1)
with ciprofloxacin MIC24 mg/L.
WGS data showed the enteric fever cases were caused by a
diverse population of pathogens, comprising six distinct S. Typhi
genotypes (Figure S1): 4.3.1 (N=89, 88%), 3.3.1 (N=7, 7%), 2.2.2
(N=2, 2%), 2.5.1 (N=1, 1%), 3.0.1 (N=1, 1%) and 3.1.1 (N=1,
1%). The dominant 4.3.1 (H58) genotype was further stratified
into lineage I (4.3.1.1, N=22, 21.8%) and lineage II (4.3.1.2,
N=67, 66.3%). All 21 QRDR triple mutants were genotype
4.3.1.2, indicating 31% frequency of fluoroquinolone resistance
in this lineage. The S. Paratyphi A population comprised A1, C4
and C5 lineages (Figure S2).
For regional and global contextualization, whole-genome phy-
logenies were constructed including S. Typhi 4.3.1.2 from this study
and from previously published global collections.5,9 This S. Typhi
4.3.1.2 tree comprised 434 isolates inferred from an alignment
length of 1235 SNPs. S. Typhi 4.3.1.2 isolated in Bengaluru were
not monophyletic in the tree; rather they formed multiple distinct
clades intermingled with other isolates from India, Nepal and
Bangladesh, indicating broad regional circulation. The most recent
common ancestor (MRCA) of Bengaluru isolates was the MRCA of
Table 1. Genetic determinants of fluoroquinolone resistance in the Indian isolates
Source
S. Typhi (n=101) S. Paratyphi A (n=14)
Totaladults children adults children
Number of isolates 68 33 10 4 115
Fluoroquinolone non-susceptible 67 (99%) 31 (94%) 9 (90%) 3 (75%) 110 (96%)
Any QRDR mutation 67 (99%) 32 (97%) 10 (100%) 4 (100%) 113 (98%)
3 QRDR mutations (gyrA S83F, gyrA D87N, parC S80I) 12 (18%) 9 (27%) 0 0 21 (18%)
2 QRDR mutations 12 (18%) 4 (12%) 0 0 16 (14%)
gyrA S83F, parC E84G 6 (9%) 3 (9%) 0 0
gyrA S83F, parE A364V 4 (6%) 1 (3%) 0 0
gyrA S83Y, parE A364V 1 (1%) 0 0 0
gyrA D87N, parE A364V 1 (1%) 0 0 0
1 QRDR mutation 43 (63%) 19 (58%) 10 (100%) 4 (100%) 74 (64%)
gyrA S83F 7 (10%) 4 (12%) 7 (70%) 3 (75%)
gyrA S83Y 34 (50%) 15 (45%) 3 (30%) 1 (25%)
gyrA D87N 1 (1%) 0 0 0
gyrB S464F 1 (1%) 0 0 0
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all South Asian S. Typhi 4.3.1.2 (Figure 1), supporting the hypothesis
that this genotype emerged in India and has since been circulating
in the region. The triple mutants isolated in Bengaluru formed a
monophyletic clade with those observed previously in both India
and Nepal4,6 (Figure 1), indicating a single emergence event
in India followed by ongoing clonal expansion, leading to both
persistence in India and regional spread.
Discussion
In the absence of a reliable public health surveillance system,
these data potentially reflect the occurrence of enteric fever in this
South Indian setting and the high-resolution data obtained as a
result of pathogen WGS enabled insight into the composition
of the circulating population structure and contextualization of
strains on a regional and global level. The close genetic relatedness
of S. Typhi isolated in South Asia (Figure 1), including the
fluoroquinolone-resistant clone, indicates inter-regional transmis-
sion and suggests that enteric fever prevention strategies require a
coordinated approach between these countries. Similar findings
exist with regard to the S. Paratyphi A population, in which strains
belonging to the A1 lineage cluster with those of other countries
of South Asia while lineages C4 and C5 cluster more closely with
those of China and South-East Asia (Figure S2). The lack of an
S. Paratyphi A vaccine limits prevention options.
The dominance of the 4.3.1 genotype in this study is consistent
with recent reports from other endemic regions of South Asia,
South-East Asia and East and Southern Africa. However further
characterization of the 4.3.1 population revealed a greater domin-
ance of lineage 4.3.1.2 compared with lineage 4.3.1.1, potentially
associated with local selection from fluoroquinolone use.10
Notably, no MDR (i.e. combined resistance to ampicillin, co-
trimoxazole and chloramphenicol)5,6 was observed in this study.
This is in contrast with recent data from Bangladesh that identified
4.3.1.1 as a dominant genotype, which in that setting was associ-
ated with QRDR triple mutants and MDR.11 Cephalosporins and
azithromycin are currently the first-line treatment for enteric fever
in the majority of South Asian settings. No cephalosporin resist-
ance was detected in these isolates; however, it is anticipated that
this could emerge via the acquisition of plasmid-encoded ESBL
genes, as has recently been observed among S. Typhi isolates from
other parts of India and neighbouring Pakistan.12–15
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Figure 1. Maximum likelihood phylogenetic tree of 4.3.1.2 (H58 lineage II) S. Typhi isolates from Bengaluru in context with available WGS data from
South Asia. The fluoroquinolone-resistant QRDR triple-mutant clone is shown in light green. Branches and rings are coloured according to the inset le-
gend. Branch lengths are indicative of the estimated substitution rate per variable site; the tree was outgroup rooted using S. Paratyphi A strain
AKU_12601. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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Our study has limitations as all isolates examined were from a
single hospital-based passive surveillance programme and thus
may not be representative of the disease trends in the wider com-
munity. We also did not actively survey all febrile cases coming to
the hospital and it is known that hospital-based active surveillance
of enteric fever yields a higher number of cases.16 However, data
from a global collection including isolates from India and from
Nepal suggest the genotypes obtained from this study are fairly
representative of strains circulating in the region and provide inter-
esting insight into the molecular structure of the local pathogen
population. The other limitations are related to issues intrinsic to
the currently available tools used for diagnosis, sequencing and
bioinformatic pipelines. These include the low sensitivity of blood
culture, the use of short-read sequencing technology and the reli-
ance on an exhaustive list of genes and SNPs to identify molecular
mechanisms of AMR in these isolates.
Conclusions
These data, we believe, constitute the first genomic surveillance
study of blood culture-confirmed enteric fever in India, and provide
valuable insights into the circulating pathogen population. Of par-
ticular concern is the emergence and expansion of the highly
fluoroquinolone-resistant triple-mutant S. Typhi clone, which was
responsible for 18% of all enteric fever cases in this setting. Its on-
going inter- and intra-country transmission in South Asia highlights
the need for regional coordination of intervention strategies,
including vaccination but also infrastructure improvements to sup-
port hygiene and sanitation.
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